Pfizer's obesity asset berobenatide (PF-08653944 / MET-097i), acquired from Metsera for up to $10 billion, has shown robust weight loss and potential for once‑monthly dosing in mid‑stage trials.
At the 2026 American Diabetes Association (ADA) Scientific Sessions, Pfizer presented new Metsera‑related data reinforcing berobenatide as Pfizer’s entry point into the large obesity market.
Data from Phase IIb VESPER‑2 and VESPER‑3 show dose‑dependent weight loss and HbA1c improvements, with up to roughly 12–14% placebo‑adjusted weight loss at higher doses, and no plateauing after switching to monthly injection.
Analysts say the profile is competitive but Pfizer still trails established GLP‑1 leaders; however, a monthly regimen and tolerability profile could differentiate it and meet unmet patient needs.
Sources:
Metsera asset data support Pfizer's 'entry point' into obesity market
ADA: Pfizer pads case for berobenatide in obesity, adding validation ...
Pfizer's Early Metsera Data Leaves Analysts Wanting More - BioSpace
Pfizer dips on new data for obesity drug acquired in $10B deal
Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and ...
Pfizer's First Weight-Loss Data After Metsera Buy 'Look ...
Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet - YouTube
Obesity data weigh on Pfizer shares, but growing pipeline has ...
Pfizer CEO: Metsera deal gives us 'one of the most ... - YouTube
Pfizer's new prize Metsera touts 14.1% weight loss for GLP-1
Detailed data show Pfizer's monthly obesity drug continues to show ...
JPM26: Pfizer Fast-Tracks Obesity Programs in Race ...
The Pfizer–Metsera $10B Deal - MSQ Ventures
Pfizer amps up push into obesity treatments with $4.9B deal ...
JPM26: Pfizer's Metsera deal supercharges its obesity strategy